A bioinformatics approach for precision medicine off-label drug selection among triple negative breast cancer patients

Journal of the American Medical Informatics Association

Volumn 23, Issue 4, 2016, Pages 741-749

  Cheng, Lijun ^a   Schneider, Bryan P ^a   Li, Lang ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Bioinformatics; Drug selection; Precision medicine

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 6; DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FRIZZLED PROTEIN; GAMMA GLUTAMYL HYDROLASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN TYROSINE KINASE; SMOOTHENED PROTEIN; THYMIDYLATE SYNTHASE; DNA;

ARTICLE; BIOINFORMATICS; CANCER PATIENT; COPY NUMBER VARIATION; DRUG APPROVAL; DRUG CHOICE; DRUG POTENCY; DRUG SCREENING; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE MUTATION; HUMAN; KNOWLEDGE BASE; MOLECULARLY TARGETED THERAPY; OFF LABEL DRUG USE; PATIENT CODING; PERSONALIZED MEDICINE; TRIPLE NEGATIVE BREAST CANCER; ALGORITHM; BIOLOGY; DNA SEQUENCE; FEMALE; GENETIC DATABASE; GENETICS; TUMOR CELL LINE;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DNA, NEOPLASM; FEMALE; HUMANS; KNOWLEDGE BASES; OFF-LABEL USE; PRECISION MEDICINE; SEQUENCE ANALYSIS, DNA; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84981185464     PISSN: 10675027     EISSN: 1527974X     Source Type: Journal    
DOI: 10.1093/jamia/ocw004     Document Type: Article

References (26)

1. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546-1558.
2. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-795.
3. Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86(1):97-100.
4. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discovery. 2011;1(1):44-53.
5. Do K, O'Sullivan Coyne G, Chen AP, An overview of the NCI precision medicine trials-NCI MATCH and MPACT. Chin Clin Oncol. 2015; 4(3):31.
6. Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. J Clin Oncol. 2015; 33(23):2563-77.
7. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333-339.
8. Zack TI, Schumacher SE, Carter SL, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013;45(10):1134-1140.
9. Conti RM, Bernstein AC, Villaflor VM, et al. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population- based cohort of medical oncologists. J Clin Oncol. 2013;31: 1134-1139.
10. Fairman KA, Curtiss FR. Regulatory actions on the off-label use of prescription drugs: Ongoing controversy and contradiction in 2009 and 2010. J Manag Care Pharm. 2010;16:629-639.
11. American Society of Clinical Oncology. Reimbursement for cancer treatment: coverage of off-label drug indications. J Clin Oncol. 2006;24: 3206-3208.
12. Poole SG, Dooley MJ. Off-label prescribing in oncology. Support Care Cancer. 2004;12:302-305.
13. http://www.broadinstitute.org/ccle/home.
14. Daemen A, Griffith OL, Heiser LM, et al. Modeling precision treatment of breast cancer. Genome Biol. 2013;14(10):R110.
15. Ettinger DS, Kuettel M, Malin J, et al. NCCN roundtable: what are the characteristics of an optimal clinical practice guideline? J Natl Compr Canc Netw. 2015;13:640-642.
16. Barretina J, Caponigro G, Stransky N, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603-607.
17. Tomczak K, Czerwinska P, Wiznerowicz M, et al. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemporary Oncol. 2015;19(1A):A68-A77.
18. Basu A, Bodycombe NE, Cheah JH, et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell. 2013;154:1151-1161.
19. O'Toole SA, Beith JM, Millar EK, et al. Therapeutic targets in triple negative breast cancer. J Clin Pathol. 2013;66(6):530-542.
20. Ellis ML, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discovery. 2013;3(1):27-34.
21. Forbes SA, Tang G, Bindal N, et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 2010;38(Database issue):D652-D657.
22. Cancer Genome Atlas N: Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
23. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm406387.htm.
24. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24:7455-7464.
25. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer, Ann Oncol. 2007;18(6):977-984.
26. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-2767.